2017 Rock Docs Coming Soon!

Meet the 2016 Rock Docs

See past Rock Docs »

Majella Doyle, MD, MBA, FRCS

Dr. Doyle received her medical degree from Royal College of Surgeons in Ireland. After completing her residency in Ireland, Dr. Doyle came to St. Louis and completed two fellowships at Washington University School of Medicine, one in Hepatobiliary, Pancreatic and Liver Transplant Surgery, and the other in Abdominal Organ Transplant. Dr. Doyle also received an MBA from Washington University in St. Louis. Her specialty areas are liver surgery and transplantation, hepatobiliary surgery, hepatobiliary pancreatic cancer, and pancreatic surgery. Dr. Doyle’s research interests focus on surgical clinical outcomes.




Gavin Dunn, MD, PhD

Dr. Dunn received his MD and PhD from Washington University in St. Louis with a focus on pathology and immunology. During his residency, Dr. Dunn served as Lieutenant Commander for the United States Navy Reserve Medical Corps. Dr. Dunn currently serves as a faculty member in the Department of Neurological Surgery with an appointment in the Department of Pathology and Immunology at Washington University. He oversees a research program focused on immunobiology of malignant glioma, a complex brain tumor. His team’s research goal is to develop novel translational and clinical trial efforts in the treatment of this disease.



Michael Naughton, MD

Dr. Naughton completed his fellowship in hematology and oncology at Washington University School of Medicine. Since 2001, Dr. Naughton has served as the assistant professor of medicine in the Medical Oncology Division. Dr. Naughton’s clinical research is focused on the treatment of breast cancer, specifically to design treatment strategies for women with early stages of breast cancer to optimize long-term outcomes.




Monica Shokeen, PhD, MBA

After receiving her MBA in international business in India, Dr. Shokeen, received her PhD and completed her postdoctoral fellowship at Washington University in St. Louis. Dr. Shokeen’s research is focused on small molecule and macromolecular agents for imaging and targeted drug delivery for cancer and cardiovascular diseases. Dr. Shokeen is leading the development of novel contrast agents that detects multiple myeloma with high accuracy. This work will allow doctors to monitor how patients are responding to treatment and target specific treatments to appropriate patients.